Table 3 The volume of tumor and anti- tumor rate.

From: Therapeutic effects of long-circulating miR-135a-containing cationic immunoliposomes against gallbladder carcinoma

Group

Volume (mm3)

The anti-tumor rate of 25d (%)

15d

17d

19d

21d

23d

25d

Control

107.99 ± 16

295.82 ± 40

670.61 ± 104

1031.86 ± 165

1252.45 ± 259

1441.46 ± 249

—

Anti-EGFR- CIL-pWPXL

103.74 ± 32

310.13 ± 148.13

598.15 ± 235

1014.98 ± 254

1319.15 ± 319.16

1634.39 ± 243

−0.13

pWPXL-miR- 135a

105.6 ± 17

179.9 ± 72.05

423.98 ± 137.02

643.6 ± 195.36

1002.03 ± 225

1320.35 ± 217

0.08

LCL-miR- 135a

105.94 ± 21

213.84 ± 80

440.28 ± 176

531.18 ± 189.59

661.97 ± 180

754.68 ± 209

0.48

Anti-EGFR- CIL-miR-135a

117.18 ± 23

187.28 ± 60.31

305.5 ± 107

400.16 ± 155

512.9 ± 171

574.97 ± 184

0.60

  1. Tumour volumes in mice bearing GBC xenografts on days 15, 17, 19, 21, 23, and 25 after inoculation and anti-tumour rates on day 25 after inoculation. Data are expressed as the mean ± SD (n = 8).
Back to article page